- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02451839
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) (VITALITY)
For public health purposes disability is becoming increasingly important as an outcome measure. Despite this, there are few data on the effectiveness of adalimumab on disability outcomes in patients with immune-mediated inflammatory diseases (IMIDs), particularly in the Phase IV setting. There are even less data available in New Zealand, which did not have the opportunity to participate to a major extent in large, multinational, Phase III pivotal studies of adalimumab in IMIDs.
The World Health Organisation Disability Assessment Schedule (WHODAS) 2.0 is a simple, validated, free and easy-to-use generic assessment instrument for health and disability. It is applicable across cultures, in all adult populations. It is a responsive measure that can show what difference a treatment makes.
Results from study of effect of adalimumab on WHODAS scores and other patient-reported outcomes (PROs) of work activity and well-being will be of interest to a variety of stakeholders in the healthcare system including patients, healthcare practitioners and payers.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Patients with a diagnosis of rheumatoid arthritis, Crohn's disease or psoriasis who have made a decision with their physician to commence treatment with adalimumab in accordance with routine medical practice and with the approved adalimumab New Zealand Datasheet.
- Patients who have been evaluated for tuberculosis risk factors/exposure for active/latent tuberculosis infection (per local requirements and according to the approved adalimumab New Zealand Datasheet).
- Adult subjects, 18-75 years old, who have voluntarily signed and dated an informed consent form prior to any study-specific procedures.
Exclusion Criteria:
- Previous treatment with adalimumab.
- Previous treatment with any biologic.
- Severe infection including sepsis, active tuberculosis or opportunistic infection.
- Moderate to severe heart failure (New York Heart Association Class II/III).
- Concurrent administration with anakinra.
- Hypersensitivity to adalimumab or its excipients.
- Any condition that in the opinion of the investigator would compromise the subject's well-being or ability to perform the study requirements.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
---|
Crohn's Disease
Participants with Crohn's disease.
All participants will receive at least 3 months of treatment with adalimumab.
Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
|
Rheumatoid Arthritis
Participants with rheumatoid arthritis.
All participants will receive at least 3 months of treatment with adalimumab.
Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
|
Psoriasis
Participants with psoriasis.
All participants will receive at least 3 months of treatment with adalimumab.
Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications
Tijdsspanne: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change From Baseline in WHODAS 2.0 Response Score at Month 2 Across All Indications
Tijdsspanne: Baseline, Month 2
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 2
|
Change From Baseline in WHODAS 2.0 Response Score at Month 4 Across All Indications
Tijdsspanne: Baseline, Month 4
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 4
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Crohn's Disease
Tijdsspanne: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 In Participants With Psoriasis
Tijdsspanne: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Rheumatoid Arthritis
Tijdsspanne: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Absenteeism
Tijdsspanne: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Presenteeism
Tijdsspanne: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
Change From Baseline in WPAI:GH 2.0 Score at Month 6 Across All Indications: Work Productivity Loss
Tijdsspanne: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Activity Impairment
Tijdsspanne: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
Change From Baseline in K10 at Month 6 Across All Indications
Tijdsspanne: Baseline, Month 6
|
The K10 is intended to yield a global measure of distress based on a questionnaire about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period.
The K10 scale involves 10 questions about emotional states each with a 5-level response scale.
Each item is scored from 1=none of the time to 5=all of the time.
Scores of the 10 items are then summed, yielding a minimum score of 10 and a maximum score of 50.
Low scores indicate low levels of psychological distress and high scores indicate high levels of psychological distress.
|
Baseline, Month 6
|
Change From Baseline in Flourishing Scale at Month 6 Across All Indications
Tijdsspanne: Baseline, Month 6
|
The Flourishing Scale is a brief 8-item summary measure of the respondent's self-perceived success in important areas such as relationships, self-esteem, purpose, and optimism.
The scale provides a single psychological well-being score.
Participants are asked to respond to 8 statements using a scale of 1 (strongly disagree) and 7 (strongly agree) for each item.
The possible range of scores is from 8 (lowest possible) to 56 (highest possible), with higher scores representing more psychological resources and strengths.
|
Baseline, Month 6
|
Change From Baseline in Subjective Vitality Scale at Month 6 Across All Indications
Tijdsspanne: Baseline, Month 6
|
The Subjective Vitality Scale assesses the state of feeling alive and alert to having energy available to the self.
Patients respond to eight prompts, with a response ranging from 1=strongly disagree to 7=strongly agree.
The sum of the scores is calculated with a higher score indicating a better condition.
The total score ranges from 8 to 56 with a higher score indicating a better condition.
|
Baseline, Month 6
|
Change From Baseline in HAQ-DI Score at Month 6 in Participants With Rheumatoid Arthritis
Tijdsspanne: Baseline, Month 6
|
HAQ-DI measures functional status in rheumatic diseases.
It has 20 items, and asks patients to report the degree of difficulty faced in several areas of their life including: dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities based on the previous week on a scale from 0 (without any difficulty) to 3 (cannot be done at all).
It also asks the participant to rate their pain and health in the previous week.
Scores on each task are summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high-dependency disability).
|
Baseline, Month 6
|
Change From Baseline in SIBDQ Score at Month 6 in Participants With Crohn's Disease
Tijdsspanne: Baseline, Month 6
|
The SIBDQ is a simple validated, 10-item questionnaire designed to find out how the patient has been feeling in the previous 2 weeks.
QoL is measured in 4 domains: bowel symptoms, emotional health, systemic systems and social function.
Participants respond to questions ranging from 1=all of the time to 7=none of the time.
Scores are added together, with higher scores indicating a better health-related QoL.
Total scores range from 10 (poor QoL) to 70 (good QoL).
|
Baseline, Month 6
|
Change From Baseline in DLQI Score at Month 6 in Participants With Psoriasis
Tijdsspanne: Baseline, Month 6
|
The DLQI measures 10 items covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, to determine how much the patients skin problem affected their life in the past week.
Participants respond to the questions with 'very much,' 'a lot,' 'a little,' or 'not at all.'
The scores are added together, and the impact on QoL is banded as follows: 0-1=no effect on participant's life; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.
|
Baseline, Month 6
|
Number of Participants Remaining on Treatment at Month 6
Tijdsspanne: Month 6
|
The number of participants at 6 months who remained on adalimumab, having satisfied the requirements for application for renewal of subsidy by special authority.
|
Month 6
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- P15-345
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Reumatoïde artritis
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend